MedPath

Assessment of the Embolization of Neurovascular Lesions Using the Penumbra Smart Coil

Not Applicable
Completed
Conditions
Intracranial Aneurysm
Registration Number
NCT02729740
Lead Sponsor
Penumbra Inc.
Brief Summary

The primary objective of this study is to gather post market data on the Penumbra SMART COIL® System (Smart System) in the treatment of intracranial aneurysms and other malformations.

Detailed Description

This is a prospective, multi-center registry of patients treated in accordance with the cleared indications for the Smart System (Smart), Penumbra Coil 400TM (PC 400), and Penumbra Occlusion Device (POD®). Data for each patient are collected in accordance with the standard of care at each participating hospital through one-year follow-up. Approximately 1,000 patients with intracranial aneurysms or other malformations treated by the Smart System at up to 100 centers will be enrolled. It is anticipated patient enrollment will take 3 years. All patients are to be assessed in accordance with the standard of care at each participating hospital through one year follow-up.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
995
Inclusion Criteria

Patients enrolled in this study must sign the Informed Consent Form and be treated according to the cleared indications for the Smart, PC 400, and POD, which include the embolization of:

  • Intracranial aneurysms
  • Other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae
Exclusion Criteria
  • Life expectancy less than one year
  • Smart, PC 400, or POD account for less than 75% of total number of coils implanted
  • Participation in another clinical investigation that could confound the evaluation of the registry device

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Number of Times Re-access With Guidewire Was Required Due to Catheter KickoutImmediate Post Procedure

Re-access attempts due to catheter kick-out across all coils

Number of Participants Achieving Adequate Occlusion Immediate Post ProcedureImmediate Post Procedure

Based on investigator's adjudication of adequate occlusion given anatomical and other considerations immediate post-procedure.

Number of Procedural Device-related Serious Adverse Events at Immediate Post-procedureImmediate Post Procedure
Number of Participants Requiring Retreatment Through Follow-upOne year from enrollment
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (72)

Southeast Alabama Medical Center

🇺🇸

Dothan, Alabama, United States

Banner Desert Medical Center

🇺🇸

Mesa, Arizona, United States

Banner University Medical Center - Phoenix

🇺🇸

Phoenix, Arizona, United States

BNI

🇺🇸

Phoenix, Arizona, United States

Banner - University Medical Center Tucson

🇺🇸

Tucson, Arizona, United States

Community Regional

🇺🇸

Fresno, California, United States

Loma Linda Medical Center

🇺🇸

Loma Linda, California, United States

Mercy San Juan

🇺🇸

Sacramento, California, United States

Cottage Hospital

🇺🇸

Santa Barbara, California, United States

University of Colorado

🇺🇸

Aurora, Colorado, United States

Scroll for more (62 remaining)
Southeast Alabama Medical Center
🇺🇸Dothan, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.